Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Percheron Therapeutics ( (AU:PER) ) has provided an announcement.
Percheron Therapeutics has secured an exclusive worldwide license from Hummingbird Bioscience to develop, manufacture, and commercialize HMBD-002, a phase II-ready immuno-oncology drug candidate. The company has completed the transfer of the Investigational New Drug application with the US FDA, positioning itself as the formal sponsor of HMBD-002. This strategic move is expected to enhance Percheron’s pipeline, with plans to initiate a phase II clinical trial in 2026. The drug, which targets the VISTA protein to reactivate immune cells against tumors, has shown promising safety and efficacy in phase I trials, potentially positioning it as a first-in-class therapy in the oncology field.
The most recent analyst rating on (AU:PER) stock is a Buy with a A$0.25 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is an international biotechnology company specializing in the development of novel therapies for oncology and rare diseases.
Average Trading Volume: 2,296,306
Technical Sentiment Signal: Sell
Current Market Cap: A$9.79M
For an in-depth examination of PER stock, go to TipRanks’ Overview page.